Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4312 - Dedicated breast PET to predict pathological complete response after neoadjuvant chemotherapy for breast cancer.


11 Sep 2017


Poster display session


Staging Procedures (not Imaging);  Breast Cancer


Makoto Fujiwara


Annals of Oncology (2017) 28 (suppl_5): v68-v73. 10.1093/annonc/mdx364


M. Fujiwara, N. masumoto, S. Sasada, T. Kadoya, M. Okada

Author affiliations

  • Surgical Oncology, Hiroshima University, 734-8551 - Hiroshima/JP


Abstract 4312


Reports indicate that whole-body (WB) 18F-fluorodeoxyglucose (FDG) PET can predict a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). New dedicated breast PET (DBPET) can generate high-resolution images and thus might be able to predict pCR after NAC. The present study aimed to determine whether or not DbPET can predict the effects of NAC for breast cancer more effectively than WBPET.


The clinical responses of 35 consecutive patients with breast cancer (T1–4, N0–1, M0) who underwent NAC between January 2016 and January 2017 were assessed using WBPET and DBPET. We assessed maximum standardized uptake values (SUVmax), before (pre-SUVmax) and after (post-SUVmax) NAC and rates of change in SUVmax (ΔSUVmax) before and after NAC. Relationships between these parameters and pathological responses (pCR) were assessed using each modality. We created receiver operating characteristics curves (ROC), calculated areas under them (AUC) for both WBPET and DBPET images and predicted pCR.


Twelve of 35 patients achieved pCR. The median pre-SUVmax, post-SUVmax and ΔSUVmax among the 35 patients determined using WBPET and DBPET were 6.8 and 18.0, 1.7 and 3.1, and 78.2 and 77.6, respectively. Uptake of 18F-FDG was indistinguishable from background in WBPET, but confirmed in DBPET after NAC in three of 23 patients with non-pCR disease. The median pre-SUVmax of WBPET and DBPET in the pCR group was higher than non-pCR group (7.88 and 21.73 vs 6.22 and 16.28, p = 0.30 and p = 0.15, respectively). In contrast, post-SUVmax of the pCR group was lower than non-pCR group (0.97 and 2.06 vs 1.54 and 3.86, p = 0.062 and p = 0.032, respectively). ΔSUVmax of pCR group was higher than non-pCR group (82.23 and 88.56 vs 76.34 and 72.55, p = 0.27 and p = 0.04, respectively). Additionally, the AUC of DBPET (pre-SUVmax: 0.543, post-SUVmax: 0.725, ΔSUVmax: 0.752) was higher than WBPET (pre-SUVmax: 0.477, post-SUVmax: 0.694, ΔSUVmax: 0.549) in either time points.


The diagnostic accuracy of DBPET were equal to, or better than those of WBPET. DBPET might serve as a new diagnostic modality when planning therapeutic strategies for patients with breast cancer after neoadjuvant chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Hiroshima University




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.